All Articles
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy. Read More ›
A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›
Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM. Read More ›
Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment. Read More ›
Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone. Read More ›
Practices and patients are now coming forward to explain how these programs have put individuals, patient assistance programs (PAPs), foundations, and other patient support systems at risk. Read More ›
For the oncology community, social media has fostered a network where patients, caregivers, and their families can connect to medical professionals as equal stakeholders, sharing education, ideas, research, feedback, and reassurance. In this exchange, medical professionals often learn as much as they teach from patients, patients’ families, and other members of the community. Read More ›
Ibrutinib (Imbruvica) may allow patients with newly diagnosed mantle-cell lymphoma (MCL) to forego autologous stem-cell transplantation (ASCT), according to results of the 3-arm randomized TRIANGLE clinical trial presented at the 64th American Society of Hematology Annual Meeting and Exposition. Read More ›
By William King
Results from the IFM2017-03 trial showed that a dexamethasone-sparing regimen of daratumumab (Darzalex) plus lenalidomide (Revlimid; DR) was superior to lenalidomide plus dexamethasone (Rd) in terms of response rates and rates of minimal residual disease (MRD) negativity in frail patients with newly diagnosed multiple myeloma. Read More ›